Welcome to our dedicated page for EDAP TMS SA SEC filings (Ticker: FOCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EDAP TMS SA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EDAP TMS SA's regulatory disclosures and financial reporting.
FocalTherics (FOCL) reported preliminary, unaudited second-quarter 2026 figures focused on its HIFU segment, now presented as continuing operations. The ESWL and Distribution segments met criteria to be classified as held for sale and are reported as discontinued operations, reflecting a strategic shift expected to significantly affect operations and financial results. Cash, cash equivalents and short-term investments from all operations totaled $21.5 million as of June 30, 2026.
The company is advancing its Focal One Robotic HIFU platform into new indications. Feasibility studies for benign prostatic hyperplasia are underway in and outside the United States. For deep infiltrating endometriosis, development includes a randomized controlled pivotal study, a limited commercial launch in Europe under a CE mark, and an FDA Breakthrough Device Designation in the United States, where the indication remains investigational.
EDAP TMS S.A. held its 2026 Annual General Meeting on June 26, 2026, where shareholders approved multiple governance and capital-related resolutions. A total of 37,484,065 Ordinary Shares, including those represented by American Depositary Shares, were represented and voted.
Shareholders renewed the terms of all nominated directors, ratified the temporary appointment of David Horn, approved related-person agreements, and validated the 2025 statutory and consolidated financial statements and result allocation. They also renewed the statutory auditor and backed executive compensation and annual say‑on‑pay votes.
Extensive delegations were granted to the Board to increase share capital through various issuances, including with or without preferential subscription rights, and in connection with mergers or asset contributions, as well as to grant free shares. Bylaw amendments affecting share capital, the Board of Directors, and shareholders’ meetings were approved, while a capital increase for employees in a company savings plan was not approved.